- $1.02bn
- $631.10m
- $610.79m
Annual income statement for 10X Genomics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 299 | 490 | 516 | 619 | 611 |
| Cost of Revenue | |||||
| Gross Profit | 240 | 416 | 396 | 409 | 415 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 835 | 543 | 684 | 884 | 805 |
| Operating Profit | -536 | -52.3 | -168 | -265 | -195 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -534 | -53.7 | -162 | -249 | -178 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -543 | -58.2 | -166 | -255 | -183 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -543 | -58.2 | -166 | -255 | -183 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -543 | -58.2 | -166 | -255 | -183 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.34 | -0.528 | -1.46 | -1.6 | -1.5 |